Ropivacaine Hydrochloride

Names

[ Name ]:
Ropivacaine Hydrochloride

[Synonym ]:
(2S)-N-(2,6-dimethyl-phenyl)-1-propyl-2-piperidincarboxamide hydrochloride
Ropivacaine hydrochl
piperidine-2-carboxamide hydrochloride
(S)-Ropivacaine Hydrochloride
ROPIVCACAINE HYDROCHLORIDE
UNII-35504LBE2T
L-N-n-propylpipecolic acid-2,6-xylidide hydrochloride
S-ROPIVACAINE HCL
REACTIVE YELLOW 145
(S)-N-n-propyl-(2,6)-dimethylphenyl-2-piperidine carboxamide hydrochloride
ROPIVACAINEHCL
(S)-1-propyl-2-piperidylformo-2',6'-xylidide hydrochloride
Piperidine-3-Carboxamide Hydrochloride
(S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monohydrochloride
n-(2,6-dimethylphenyl)-1-propyl-piperidine-2-carboxamide hydrochloride
Ropivacaine HCL
L-ropivacaine HCl
(S)-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride
2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-, hydrochloride (1:1)
Naropin
Ropivacainehydrochloride
Ropivacaine monohydrochloride
Ropivacaine Hydrochloride
Ropivacaine mesilate
(S)ROPIVACAINE HCL
(s)-n-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
(2S)-N-(2,6-dimethylphenyl)-1-propyl-pipecolinamide hydrochloride
(2S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride (1:1)
L-ropivacaine hydrochloride
ROPIVACAINE
2-PIPERIDINECARBOXAMIDE HYDROCHLORIDE
PIPERIDINE-2-CARBOXAMIDE HYDROCHLORIDE API
ROPIVACAINE 1-HYDRATE
S-ROPIVACAINE HYDROCHLORIDE
(2S)-2-[(2,6-Dimethylphenyl)carbamoyl]-1-propylpiperidinium chloride
MFCD02102164

Biological Activity

[Description]:

Ropivacaine hydrochloride is an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM.

[Related Catalog]:

Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel

Research Areas >> Neurological Disease

[Target]

IC50: 402.7 μM (K2P TREK-1)[1]

[In Vitro]

Ropivacaine hydrochloride shows reversible inhibition of TREK-1 channels in a concentration-dependent manner. The half-maximal inhibitory concentrations (IC50) of Ropivacaine hydrochloride is 402.7±31.8 μM.. Hill coefficient is 0.89 for Ropivacaine hydrochloride[1].

[In Vivo]

Epidural injections of Ropivacaine hydrochloride (60, 180 and 600 μg) produce immediate and reversible motor paralysis. The motor blockade effect is dose-dependent, with paralysis duration of 4.6, 14.6 and 29.5 mins, respectively. Epidural Ropivacaine hydrochloride sustained release suspension also produces significant blockade of mechanical allodynia and thermal hyperalgesia by 59.5% and 70.9%, respectively (P<0.05). Ropivacaine hydrochloride sustained release suspension also produces a mild antinociception (response to heat stimulus) but longer anti-allodynic and anti-hyperalgesic effects, with biological half-lives of 6.4±2.5 hrs and 6.8±2.9 hrs, respectively (P<0.05). Multiple daily epidural administration of Ropivacaine hydrochloride sustained release suspension prolongs the preemptive effects (P<0.05)[2].

[Cell Assay]

COS-7 cells are cultured in a 5 % CO2 humidified incubator at 37°C in Dulbecco’s Modified Eagle’s Medium containing 10 % heat-inactivated fetal bovine serum, and 1 % penicillin/streptomycin (100 U/mL and 100 μg/mL). The effect of Ropivacaine hydrochloride (10, 50, 100, 200, and 400 μM) on TREK-1 channels are investigated in COS-7 cells by using the whole cell patch clamp technique with a voltage ramp protocol ranging from -100 to 100 mV for 200 ms from a holding potential of -70 mV[1].

[Animal admin]

Adult male Wistar rats (240±20 g body weight) are used in this study. Animals are housed four per cage with thick sawdust bedding at standard room temperature, under a 12/12 hrs reversed light-dark cycle (7:00 a.m. to 7:00 p.m.) at a constant temperature of 22±2°C. All rats receive food and water ad libitum. For epidural administration of Ropivacaine hydrochloride, a polyethylene catheter is implanted into the epidural space. One hundred microliters of 0.2% Ropivacaine hydrochloride injection, 0.2% Ropivacaine hydrochloride sustained release suspension or saline is slowly injected for 30 secs through the epidural catheter, followed by 10 μL of sterile saline[2].

[References]

[1]. Shin HW, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth. 2014 Feb;28(1):81-6.

[2]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.044 g/cm3

[ Boiling Point ]:
410.2ºC at 760 mmHg

[ Molecular Formula ]:
C₁₇H₂₇ClN₂O

[ Molecular Weight ]:
310.862

[ Flash Point ]:
201.9ºC

[ Exact Mass ]:
310.181183

[ PSA ]:
32.34000

[ LogP ]:
4.31930

[ Storage condition ]:
2-8℃

Safety Information

[ HS Code ]:
2933399090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2933399090

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%